Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 24.71% is 15% below its 5-year average of 29.21%, near the high end of its 5-year range (-60.72%–43.49%).
1.72% below its 12-month average of 25.14%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 30.12%.
EBITDA MARGIN
24.71%
EBITDA MARGIN AVG TTM
25.14%
EBITDA MARGIN AVG 3Y
32.12%
EBITDA MARGIN AVG 5Y
29.21%
EBITDA MARGIN AVG 10Y
23.55%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.72%
CURRENT VS 3Y AVG
-23.06%
CURRENT VS 5Y AVG
-15.40%
CURRENT VS 10Y AVG
+4.95%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lantheus Holdings, Inc.
Market Cap
$6.50B
EBITDA Margin
24.71%
TTM Avg
25.14%
3Y Avg
32.12%
5Y Avg
29.21%
Market Cap
$6.49B
EBITDA Margin
21.42%
TTM Avg
19.40%
3Y Avg
15.87%
5Y Avg
16.39%
Market Cap
$6.57B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$6.66B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
Market Cap
$6.25B
EBITDA Margin
-100.49%
TTM Avg
-151.66%
3Y Avg
-322.50%
5Y Avg
-1329.03%
Market Cap
$6.02B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$5.94B
EBITDA Margin
30.20%
TTM Avg
18.88%
3Y Avg
24.58%
5Y Avg
33.74%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | $6.50B | 24.71% | 25.14% | 32.12% | 29.21% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 21.42% | 19.40% | 15.87% | 16.39% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.57B | 6.82% | 6.08% | -0.44% | -8.67% |
| Immunovant, Inc. (IMVT)vs › | $6.55B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.66B | 15.93% | 16.80% | 17.55% | 18.41% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.25B | -100.49% | -151.66% | -322.50% | -1329.03% |
| GRAIL Inc. (GRAL)vs › | $6.02B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Alkermes plc (ALKS)vs › | $7.00B | 19.05% | 23.95% | 20.94% | 15.97% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 30.20% | 18.88% | 24.58% | 33.74% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.91B | -139.44% | -176.89% | -12100.88% | -12100.88% |
Gross Margin
60.1%
EBITDA Margin
24.7%
Operating Margin
19.4%
Net Margin
17.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 30.12% |
| 2026-03-31 | 27.56% |
| 2025-12-31 | 24.58% |
| 2025-09-30 | 16.67% |
| 2025-06-30 | 26.77% |
| 2025-03-31 | 31.04% |
| 2024-12-31 | 33.53% |
| 2024-09-30 | 39.82% |
| 2024-06-30 | 29.83% |
| 2024-03-31 | 31.31% |
| 2023-12-31 | 43.08% |
| 2023-09-30 | 39.70% |
| 2023-06-30 | 43.49% |
| 2023-03-31 | 1.75% |
| 2022-12-31 | -60.72% |
| 2022-09-30 | 40.91% |
| 2022-06-30 | 33.66% |
| 2022-03-31 | 33.85% |
| 2021-12-31 | -17.86% |
| 2021-09-30 | -1.95% |
| 2021-06-30 | -16.97% |
| 2021-03-31 | 25.67% |
| 2020-12-31 | 8.35% |
| 2020-09-30 | 3.71% |
| 2020-06-30 | -2.29% |
| 2020-03-31 | 11.97% |
| 2019-12-31 | 17.88% |
| 2019-09-30 | 13.73% |
| 2019-06-30 | 20.76% |
| 2019-03-31 | 22.53% |
| 2018-12-31 | 23.56% |
| 2018-09-30 | 22.43% |
| 2018-06-30 | 22.69% |
| 2018-03-31 | 22.67% |
| 2017-12-31 | 16.52% |
| 2017-09-30 | 20.73% |
| 2017-06-30 | 25.90% |
| 2017-03-31 | 22.23% |
| 2016-12-31 | 23.14% |
| 2016-09-30 | 22.50% |
| 2016-06-30 | 24.31% |
| 2016-03-31 | 29.11% |
| 2015-12-31 | 21.62% |
| 2015-09-30 | 23.59% |
| 2015-06-30 | 13.38% |
| 2015-03-31 | 26.06% |
| 2014-12-31 | 19.71% |
| 2014-09-30 | 18.70% |
| 2014-06-30 | 19.66% |
| 2014-03-31 | 18.38% |
| 2013-12-31 | 2.97% |
| 2013-09-30 | 4.05% |
| 2013-06-30 | 4.69% |
| 2013-03-31 | -2.85% |
| 2012-12-31 | 7.32% |
